Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Khanna, D; Denton, CP; Lin, CJ; van Laar, JM; Frech, TM; Anderson, ME; Baron, M; ... Furst, DE; + view all Khanna, D; Denton, CP; Lin, CJ; van Laar, JM; Frech, TM; Anderson, ME; Baron, M; Chung, L; Fierlbeck, G; Lakshminarayanan, S; Allanore, Y; Pope, JE; Riemekasten, G; Steen, V; Müller-Ladner, U; Spotswood, H; Burke, L; Siegel, J; Jahreis, A; Furst, DE; - view fewer (2017) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 10.1136/annrheumdis-2017-211682 . (In press). Green open access

http://ift.tt/2hHLNa8